Shots:
- The MHRA has granted conditional marketing authorization to Imdylltra for treating adults with ES-SCLC, whose disease progressed post prior 2 lines of treatment. Further evaluation is underway
- This authorization was supported by P-II (DeLLphi-301) study assessing Imdylltra (10mg, Q2W) in ES-SCLC patients (N=99). It showed ORR of 41% & mDoR of 9.7mos.
- Imdylltra (tarlatamab) is a bispecific T-cell engager that binds to DLL3 on tumor cells and CD3 on T cells, activating T cells to release inflammatory cytokines and cytotoxic proteins for the destruction of DLL3+ tumor cells
Ref: BussinesNewsWire| Image: Amgen
Related News:- Amgen Reports 52 Weeks Data from P-II Trial of Maritide in Obese People with or without Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
